Publication | Closed Access

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

Surgical OncologyGastrointestinal OncologyMedicineGastroenterologyPhase Ii StudyIntravenous Exatecan MesylateSurgeryCancer TreatmentOncologyRadiation OncologyCancer ResearchMetastatic Adenocarcinoma